Regentis Biomaterials (NYSE American: RGNT) announced it has received approval from the European Notified Body to manufacture GelrinC(R) using its next-generation solvent-free manufacturing process, a milestone that supports the product's planned commercial launch in Europe. The company said the new process increases production yield by approximately 400%, producing five times more product from the same manufacturing volume while improving manufacturing efficiency, scalability and occupational and environmental safety. Extensive clinical testing validated consistent product quality and clinical performance.
GelrinC(R), which has already received CE Mark approval in Europe, is a proprietary, cell-free hydrogel implant designed to regenerate cartilage through a minimally invasive 10-minute procedure. Regentis said commercialization will be supported through its expanding European Centers of Excellence, surgeon training programs and collaborations with leading orthopedic institutions, including Humanitas Research Hospital in Milan, targeting a U.S. cartilage repair market valued at approximately $3 billion.
According to the press release, the new manufacturing process eliminates solvents, enhancing safety for workers and the environment while significantly boosting output. This development is critical for meeting anticipated demand in Europe and eventually the United States, where no off-the-shelf treatment is currently available for the approximately 470,000 annual cartilage knee repair cases. The company's Gelrin platform technology uses synchronized, degradable hydrogel implants that regenerate damaged or inflamed cartilage and bone.
The approval allows Regentis to scale production efficiently as it prepares for commercial launch. The company's strategy includes partnerships with leading orthopedic centers and surgeon training programs to ensure successful adoption. The U.S. market represents a significant opportunity, with the cartilage repair market valued at around $3 billion. Regentis aims to address this unmet need with a cell-free, off-the-shelf product that simplifies the surgical procedure and reduces recovery time.
Regentis Biomaterials is a regenerative medicine company focused on developing tissue repair solutions. Its lead product, GelrinC, is designed to regenerate cartilage in the knee through a minimally invasive procedure. The company's forward-looking statements highlight risks and uncertainties, but the recent approval marks a major step toward commercialization. For more information, visit the company's newsroom at https://ibn.fm/RGNT.
